



Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial



Yunes Panahi^a, Nahid Khalili^b, Ebrahim Sahebi^c, Soha Namazi^c, Željko Reiner^d,
Muhammed Majeed^e, Amirhossein Sahbekar^{f,*}

^a Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran, Iran

^b Department of Endocrinology, Tehran University of Medical Sciences, Tehran, Iran

^c Department of Pharmacotherapy, School of Pharmacy, Shiraz University of Medical Sciences, P.O. Box 1583, Shiraz, Iran

^d University Hospital Center Zagreb, Department of Internal medicine, University of Zagreb School of Medicine, Kišpatičeva 12, Zagreb, Croatia

^e Sabinsa Corporation, East Windsor, NJ, United States

^f Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE INFO

Keywords:

Curcumin
Diabetes
Cardiovascular disease
Cholesterol
Dyslipidemia
Lipoprotein(a)

ABSTRACT

Background: Type 2 diabetes (T2D) is an established risk factor for cardiovascular disease (CVD) and is associated with disturbed metabolism of lipids and lipoproteins. Curcuminoids are natural products with anti-diabetic and lipid-modifying actions but their efficacy in improving dyslipidemia in diabetic individuals has not been sufficiently studied.

Objective: To investigate the efficacy of supplementation with curcuminoids, plus piperine as an absorption enhancer, in improving serum lipids in patients with T2D.

Methods: In this 12-week randomized double-blind placebo-controlled trial, subjects with T2D (n = 118) were assigned to curcuminoids (1000 mg/day plus piperine 10 mg/day) or placebo plus standard of care for T2D. Serum concentrations of lipids including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), lipoprotein(a) [Lp(a)], and non-HDL-C were determined at baseline and at the end of trial.

Results: Between-group comparison of change in the study parameters revealed significant reductions in serum levels of TC (-21.86 ± 25.78 versus -17.06 ± 41.51 , respectively; $p = 0.023$), non-HDL-C (-23.42 ± 25.13 versus -16.84 ± 41.42 , respectively; $p = 0.014$) and Lp(a) (-1.50 ± 1.61 versus -0.34 ± 1.73 , respectively; $p = 0.001$) and elevations in serum HDL-C levels (1.56 ± 4.25 versus -0.22 ± 4.62 , respectively; $p = 0.048$) in the curcuminoids group as compared with the placebo group ($p < 0.05$). Serum TG and LDL-C changes did not show any significant difference between the study groups ($p > 0.05$).

Conclusion: Curcuminoids supplementation can reduce serum levels of atherogenic lipid indices including non-HDL-C and Lp(a). Therefore, curcuminoids supplementation could contribute to a reduced risk of cardiovascular events in dyslipidemic patients with T2D.

1. Introduction

Curcuminoids are bioactive phenols responsible for the yellow color of turmeric (*Curcuma longa* Linn.), a spice that has been used throughout the history in South Asian and Middle Eastern cuisine. Curcuminoids comprise of curcumin, demethoxycurcumin and bisdemethoxycurcumin.¹ It has been shown that curcuminoids have different beneficial pharmacological effects.^{2–6} For instance, a 9-month intervention with 1500 mg/day of curcumin in a prediabetic population

significantly lowered the number individuals who developed type 2 diabetes mellitus (T2DM).⁷ Curcuminoids have also glucose-lowering effects in patients with established T2DM.⁸ On the other hand, curcuminoids have been reported to have many antiatherogenic properties such as antiinflammatory and antioxidant activities.^{9–13} Curcuminoids lower circulating concentrations of pro-inflammatory mediators such as TNF- α , IL-1, IL-6, IL-8, adhesion molecules (ICAM, VCAM) and C-reactive protein (CRP).^{14–20} Curcuminoids have shown beneficial effects in lowering serum lipids but the evidence, particularly in high-risk

* Corresponding author at: Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, P.O. Box 91779-48564, Iran.
E-mail address: amir_sahbeb2000@yahoo.com (A. Sahbekar).

<http://dx.doi.org/10.1016/j.ctim.2017.05.006>

Received 20 May 2017; Received in revised form 24 May 2017; Accepted 25 May 2017

Available online 29 May 2017

0965-2299/© 2017 Elsevier Ltd. All rights reserved.

populations, is still insufficient.^{21–25} For instance, low doses of 80 mg/day were shown to reduce plasma triglycerides (TG) in 19 healthy middle aged subjects when compared with 19 subjects on placebo, while high doses of 1000 mg/day of curcumin reduced plasma TG in 30 obese subjects but did not affect serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C).^{26,27} The same dose was reported to reduce serum TC, LDL-C, non-HDL-C and elevated serum HDL-C in 50 patients with metabolic syndrome who were treated with standard of care.²⁸ In patients with acute coronary syndrome curcumin, in very low doses of 15, 30 and 60 mg/day as adjunct therapy, reduced TC and LDL-C and increased HDL-C levels with lower doses showing higher efficacy.²⁹ Curcuminoids were also shown to reduce TC and LDL-C and increase HDL-C levels in patients with nonalcoholic fatty liver disease (NAFLD).^{22,30}

The oral absorption of curcumin is low due to its hydrophobic nature, and its metabolism and systemic elimination are rapid, leading to a low systemic bioavailability. This issue has been resolved by using several formulation improvements, such as coadministration with absorption-enhancing adjuvants such as piperine.³¹

The effects of curcuminoids on plasma lipoproteins still remain controversial and a recently published meta-analysis could not prove any effect of curcumin supplementation on serum TC, LDL-C, triglycerides and HDL-C levels in heterogeneous populations.³² The aim of this study was therefore to evaluate the efficacy of curcuminoids plus piperine on serum lipoproteins in patients with type 2 diabetes mellitus who are by definition at a high or very high risk for atherosclerotic cardiovascular disease (CVD).³³

2. Materials and methods

2.1. Subjects

Adult subjects aged 18–65 years were recruited from those referring to the Diabetes Clinic of the Baqiyatallah Hospital (Tehran, Iran). The inclusion criteria were diagnosis of T2DM based on fasting plasma glucose (FPG) ≥ 126 mg/dL, glycated hemoglobin (HbA1C) $\geq 6.5\%$, or the use of anti-diabetic treatments. Exclusion criteria were pregnancy or breastfeeding, lack of possibility to give an informed consent, participation in a concomitant trial, presence of malignancies, chronic liver disease (alanine aminotransferase levels three times upper the limit of normal value range), renal failure (serum creatinine ≥ 2.0 mg/dL or being on dialysis), chronic inflammatory diseases such as rheumatoid arthritis and acute infections, endocrine diseases other than T2DM (e.g. hypothyroidism or hyperthyroidism), obsessive compulsive disorder, hyperglycemia due to secondary causes, receiving hormone therapy or other herbal medicines, hypersensitivity to the study medication, and lack of compliance with the study medication.

2.2. Study design

This study was designed as a randomized double-blind placebo-controlled trial with a parallel-group design and performed between June 22, 2015 and April 20, 2016. Subjects who met the mentioned inclusion criteria ($n = 118$) were randomly allocated to either curcuminoids (curcumin C3 Complex[®], Sami Labs LTD, Bangalore, India) or placebo for a period of 12 weeks. Curcuminoid and placebo capsules were matched in shape, size and color, and the color of placebo was matched to that of curcuminoid powder. To enhance the oral bioavailability of curcuminoids, 5 mg piperine (Bioperine[®]; Sami Labs LTD, Bangalore, India) was added to each 500 mg curcuminoids capsule. C3 Complex[®] preparation that was used in the present study contained the three major curcuminoids including curcumin, demethoxycurcumin and bisdemethoxycurcumin in a patented ratio.

The study protocol was approved by the Ethics Committee at the Baqiyatallah University of Medical Sciences and registered in the

Iranian Registry of Clinical Trials (code: IRCT201505301165N4). Written informed consent was obtained from all individuals.

2.3. Blood sampling and measurements

Overnight fasting blood samples were collected at baseline and at the end of the study. The samples were allowed to clot for about 30 min and then centrifuged at 750g for 10 min to obtain serum. Serum samples were aliquoted and frozen at -80°C until measurements. Weight was measured with the subjects dressed in light clothing after an overnight fasting using a standard scale. Anthropometric indices were measured as previously described. Serum concentrations of total cholesterol, LDL-C, HDL-C and triglycerides were measured using routine enzymatic methods with commercial kits. Serum levels of lipoprotein (a) [Lp(a)] were measured using immunoassay. Serum non-HDL-C concentrations were calculated by subtracting HDL-C from total cholesterol.

2.4. Statistical analysis

Statistical analyses were performed using the IBM SPSS Statistics for Windows Version 20.0 (IBM Corp., Armonk, NY, USA). Normal distribution of continuous variables was checked using Kolmogorov-Smirnov test. Data were expressed as mean \pm SD or median (interquartile range) for normally and non-normally distributed data, respectively. Within-group comparisons were performed using paired samples *t*-test or Wilcoxon signed-ranks test for normally and non-normally distributed data, respectively. Between-group comparisons were performed using independent samples *t*-test or Mann-Whitney *U* test for normally and non-normally distributed data, respectively. Comparison of categorical variables between the groups was performed using Chi-square test. In case of significant difference in baseline values, adjustment was made using univariate analysis of covariance (ANCOVA) and general linear model.

3. Results

A total of 100 subjects (50 in each group) completed the 12-week period of trial. Drop-out rate (18 patients) did not significantly differ between the groups (Fig. 1). During the trial, there was no report of any severe side effect, suggesting the safety of the administered combination.

Baseline parameters of the study groups are shown in Table 1. The serum levels of TC, TG, HDL-C, non-HDL-C and Lp(a) ($p > 0.05$) were comparable between the groups. However, baseline values of BMI ($p = 0.047$) and LDL-C ($p = 0.010$) were significantly lower in the curcuminoids group.

Within-group comparisons showed significant reductions in weight ($p < 0.001$) and BMI ($p < 0.001$) in the curcuminoids group while these parameters increased by the end of trial in the placebo group ($p = 0.020$ for weight and $p = 0.023$ for BMI). With respect to the lipid profile, significant reductions in TC, TG, LDL-C and non-HDL-C were observed in both groups. However, reduction of serum Lp(a) and increase in HDL-C concentrations were only observed in the curcuminoids group (Table 2).

Between-group comparison of change in the study parameters revealed reductions in weight (-1.44 ± 1.58 versus 0.70 ± 2.05 in the curcuminoids and placebo group, respectively; $p < 0.001$), BMI (-0.49 ± 0.52 versus 0.24 ± 0.73 ; $p < 0.001$) and serum levels of TC (-21.86 ± 25.78 versus -17.06 ± 41.51 ; $p = 0.023$), non-HDL-C (-23.42 ± 25.13 versus -16.84 ± 41.42 ; $p = 0.014$) and Lp(a) (-1.50 ± 1.61 versus -0.34 ± 1.73 ; $p = 0.001$) and elevations in serum LDL-C (-8.22 ± 13.94 versus -30.16 ± 45.40 ; $p = 0.002$) and HDL-C (1.56 ± 4.25 versus -0.22 ± 4.62 ; $p = 0.048$) levels in the curcuminoids group as compared with the placebo group. However, when post-supplementation serum levels of LDL-C or changes in serum

Download English Version:

<https://daneshyari.com/en/article/5565201>

Download Persian Version:

<https://daneshyari.com/article/5565201>

[Daneshyari.com](https://daneshyari.com)